Results 191 to 200 of about 40,021 (309)

5-HT1B receptor agonists promote Schwann cell myelination. [PDF]

PLoS One
Kobayashi-Ujiie Y, Hiraki-Kamon K, Wakatsuki S, Araki T.   +3 more
europepmc   +1 more source

Psilocybin as a novel treatment for chronic pain

British Journal of Pharmacology, Volume 183, Issue 14, Page 3992-4005, July 2026.
Abstract Psychedelic drugs are under active consideration for clinical use and have generated significant interest for their potential as anti‐nociceptive treatments for chronic pain, and for addressing conditions like depression, frequently co‐morbid with pain.
Tate Askey, Reena Lasrado, Maria Maiarú, Gary J. Stephens   +3 more
wiley   +1 more source

Oral Serotonin Receptor Agonists: A Review of Their Cost Effectiveness in Migraine

Migraine headache is a highly prevalent chronic, episodic condition. The direct and indirect costs of migraine headache have a tremendous economic impact in the US.
Jennifer H. Lofland, David B. Nash
core  

Canoe full of hot paddlers: TRPV1 neurons steering cardiorespiratory control

The Journal of Physiology, EarlyView.
Richard J. A. Wilson, Nicholas Jendzjowsky   +1 more
wiley   +1 more source

Neuropsychopharmacology of hallucinogenic and non‐hallucinogenic 5‐HT2A receptor agonists

British Journal of Pharmacology, Volume 183, Issue 14, Page 3935-3949, July 2026.
Psychedelic drugs such as LSD and psilocin were once relegated to the fringes of medical research because of their association with counterculture movements and a perceived concern about harm through recreational use, and their consequent legal prohibition in the early 1970s.
Trevor Sharp, Aurelija Ippolito
wiley   +1 more source

New and emerging treatments for PBC-related pruritus. [PDF]

Drugs Context
Anderson SL.
europepmc   +1 more source

Psychedelics, entactogens and psychoplastogens for depression and related disorders

British Journal of Pharmacology, Volume 183, Issue 14, Page 3897-3919, July 2026.
Currently, the most actively investigated rapidly acting antidepressants, anxiolytics and/or anti PTSD agents, include psychedelics e.g. psilocybin, LSD, N,N‐dimethyltryptamine, ayahuasca; non‐hallucinogenic entactogens, e.g. MDMA; psychoplastogens which rapidly promote neuroplasticity, e.g.
Daniel Hoyer
wiley   +1 more source

Clinical review of how glucagon-like peptide-1 agonist obesity medications decrease sexual desire, and a biopsychosocial model for why we don't 'see' it. [PDF]

Obes Pillars
Gelfand ST, Tveit MC, Simon JA.
europepmc   +1 more source

Evidence that 5‐HT2A receptor signalling efficacy and not biased agonism differentiates serotonergic psychedelic from non‐psychedelic drugs

British Journal of Pharmacology, Volume 183, Issue 14, Page 4058-4071, July 2026.
Background and Purpose Serotonergic psychedelic drugs are under investigation as therapies for various psychiatric disorders, including major depression. Although serotonergic psychedelic drugs are 5‐HT2A receptor agonists, some such agonists are not psychedelic, potentially due to differences in 5‐HT2A receptor ligand bias or signalling efficacy. Here,
Aurelija Ippolito, Sridhar Vasudevan, Shaun Hurley, Gary Gilmour, Frederick Westhorpe, Grant Churchill, Trevor Sharp   +6 more
wiley   +1 more source

Indole Alkaloids as Biased Opioid Receptor Modulators. [PDF]

Pharmaceuticals (Basel)
Grundmann O, Henderson A.
europepmc   +1 more source